Potential future neuroprotective therapies for neurodegenerative disorders and stroke.
The cellular mechanisms underlying neuronal loss and neurodegeneration have been an area of interest in the last decade. Although neurodegenerative diseases such as Alzheimer disease, Parkinson disease, and Huntington disease each have distinct clinical symptoms and pathologies, they all share common mechanisms such as protein aggregation, oxidative injury, inflammation, apoptosis, and mitochondrial injury that contribute to neuronal loss. Although cerebrovascular disease has different causes from the neurodegenerative disorders, many of the same common disease mechanisms come into play following a stroke. Novel therapies that target each of these mechanisms may be effective in decreasing the risk of disease, abating symptoms, or slowing down their progression. Although most of these therapies are experimental, and require further investigation, a few seem to offer promise.
Tarawneh
Rawan
R
Alzheimer Disease Research Center, Washington University School of Medicine, 4488 Forest Park Avenue, Suite 130, St Louis, MO 63108, USA.
Galvin
James E
JE
D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D028361:Mitochondrial Diseases / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D019636:Neurodegenerative Diseases / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control*; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018384:Oxidative Stress / Q000502:physiology; D011485:Protein Binding / Q000502:physiology; D017510:Protein Folding; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology; D020521:Stroke / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control*
D018836:Inflammation Mediators; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate